Cold Chain Solutions 101: How GLP-1 Medications are Shipped

The global rise in type 2 diabetes and obesity has brought glucagon-like peptide-1 (GLP-1) drugs into sharp focus. Medications such as Ozempic and Wegovy have proven to be transformative for patients managing blood sugar and weight loss, but their growing use presents new challenges for the healthcare supply chain. GLP-1 receptor agonists are temperature sensitive, requiring a tightly controlled cold chain from manufacturing to the moment they arrive at patients’ homes. 

Cold Chain for Global Biopharma 101: How Do We Protect Temperature-Sensitive Medicines Across the World?

The biopharma industry is shifting rapidly toward biologics, specialty medicines, and personalized therapies. These products are derived from living cells and are far more sensitive to temperature fluctuations than traditional chemical-based pharmaceuticals. Even a brief exposure to a temperature outside of specification can degrade the therapy, reduce efficacy, or render the product entirely unusable. In some cases, a single lost shipment means a patient misses their therapeutic window or a clinical trial experiences costly delay.